Scholar Rock Holding Corp SRRK:NASDAQ

Last Price$5.49NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.07(1.29%)
Bid (Size)$5.15 (1)
Ask (Size)$5.72 (2)
Day Low / High$5.01 - 5.49
Volume824.1 K

View Biotechnology IndustryPeer Comparison as of 06/30/2022


Scholar Rock Holding Corp ( NASDAQ )

Price: $5.49
Change: +0.07 (1.29%)
Volume: 824.1 K
4:00PM ET 6/30/2022

Precigen Inc ( NASDAQ )

Price: $1.34
Change: -0.02 (1.47%)
Volume: 713.3 K
4:00PM ET 6/30/2022

Lineage Cell Therapeutics Inc ( NYSE MKT LLC )

Price: $1.58
Change: -0.03 (1.86%)
Volume: 785.1 K
8:00PM ET 6/30/2022

Seres Therapeutics Inc ( NASDAQ )

Price: $3.43
Change: +0.28 (8.89%)
Volume: 1.3 M
4:00PM ET 6/30/2022

Alaunos Therapeutics Inc ( NASDAQ )

Price: $1.24
Change: 0.00 (0.00%)
Volume: 1.7 M
4:00PM ET 6/30/2022

Read more news Recent News

Insider Buy: Scholar Rock Holding
4:32PM ET 6/24/2022 MT Newswires

Amir Nashat, Director, on June 22, 2022, executed a purchase for 1,197,992 shares in Scholar Rock Holding (SRRK) for $5,870,161. Following the Form 4...

Piper Sandler Adjusts Scholar Rock's Price Target to $19 From $28, Maintains Overweight Rating
9:56AM ET 6/23/2022 MT Newswires

Scholar Rock (SRRK) has an average outperform rating and price target range of $6 to $55, according to analysts polled by Capital IQ. (MT Newswires covers...

Sector Update: Health Care Stocks Narrowly Stay on Positive Ground
4:03PM ET 6/17/2022 MT Newswires

Health care stocks hung on for narrow gains this afternoon, with the NYSE Health Care Index rising 0.2% and the SPDR Health Care Select Sector ETF (XLV) ...

Sector Update: Health Care
3:56PM ET 6/17/2022 MT Newswires

Health care stocks were hanging on for narrow gains this afternoon, with the NYSE Health Care Index rising 0.2% while the SPDR Health Care Select Sector...

Company Profile

Business DescriptionScholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA. View company web site for more details
Address301 Binney Street
Cambridge, Massachusetts 02142
Number of Employees65
Recent SEC Filing06/27/2022SC 13G/A
President, Chief Executive Officer & DirectorNagesh K. Mahanthappa
Chief Financial Officer & Head-Business OperationsEdward H. Myles
Chief Scientific OfficerGregory J. Carven
Chief Medical OfficerYung H. Chyung

Company Highlights

Price Open$5.29
Previous Close$5.42
52 Week Range$4.33 - 44.95
Market Capitalization$193.8 M
Shares Outstanding35.3 M
SectorHealth Technology
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.09
Beta vs. S&P 500N/A
Net Profit Margin-236.95%
Return on Equity-59.99%

Analyst Ratings as of 06/30/2022

Consensus RecommendationConsensus Icon
Powered by Factset